SIRT7 and acute myeloid leukemia: The probability of elderly patients (≥60 years old) achieving DMR was significantly reduced (odds ratio [OR] = 0.207) compared to other age groups, which may be related to the decline of immune function, the increase of comorbidities, and differences in drug metabolism occurring with age.[13] Kaiser et al[14] investigated SIRT7 expression and age-related changes in the hematopoietic system to find that aging accelerates the progression of myeloid stem cell diseases (e.g., AML, CML), providing a solid theoretical basis for age as a critical factor in treatment response.